These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11449659)

  • 21. Uncomplicated E coli urinary tract infection in college women: a retrospective study of E coli sensitivities to commonly prescribed antibiotics.
    Ansbach RK; Dybus KR; Bergeson R
    J Am Coll Health; 1995 Jan; 43(4):183-5. PubMed ID: 7860876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli.
    Gagliotti C; Buttazzi R; Sforza S; Moro ML;
    J Infect; 2008 Sep; 57(3):179-84. PubMed ID: 18707763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on drug therapy: VIII. Oral cephalosporins.
    Cuddy PG; Elenbaas JK
    J Am Med Womens Assoc (1972); 1981 Sep; 36(9):275-7, 281. PubMed ID: 6279717
    [No Abstract]   [Full Text] [Related]  

  • 24. [Strain of Escherichia coli resistant to broad-spectrum cephalosporin and amoxicillin/clavulanic acid].
    Martín-Pozo A; Alós JI
    Rev Esp Quimioter; 2012 Sep; 25(3):222-3. PubMed ID: 22987271
    [No Abstract]   [Full Text] [Related]  

  • 25. [Cefazolin. 3. Double blind controlled trial in urinary tract infections].
    Seika K; Minakawa M; Miyoshi K; Yamaji K; Sugiyama Y
    Jpn J Antibiot; 1972 Apr; 25(2):72-8. PubMed ID: 4627212
    [No Abstract]   [Full Text] [Related]  

  • 26. Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary Escherichia coli isolates.
    Burman WJ; Breese PE; Murray BE; Singh KV; Batal HA; MacKenzie TD; Ogle JW; Wilson ML; Reves RR; Mehler PS
    Am J Med; 2003 Oct; 115(5):358-64. PubMed ID: 14553870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation of cephradine oral suspension in the treatment of bacterial infections of infants and children.
    Lipman RP; Silverman W
    Clin Pediatr (Phila); 1977 Sep; 16(9):835-7. PubMed ID: 330074
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical and microbiological profile of urinary tract infection at a tertiary-care center in Lebanon.
    Fadel R; Dakdouki GK; Kanafani ZA; Araj GF; Kanj SS
    Infect Control Hosp Epidemiol; 2004 Jan; 25(1):82-5. PubMed ID: 14756226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ["Velocef squibb" in the treatment of respiratory and urinary infections (author's transl)].
    Gómez Francisco A
    Folia Clin Int (Barc); 1973 Sep; 23(9):616-21. PubMed ID: 4616857
    [No Abstract]   [Full Text] [Related]  

  • 30. Susceptibility of Escherichia coli strains isolated from outpatient children with community-acquired urinary tract infection in southern Switzerland.
    Borsari AG; Bucher B; Brazzola P; Simonetti GD; Dolina M; Bianchetti MG
    Clin Ther; 2008 Nov; 30(11):2090-5. PubMed ID: 19108796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of urinary tract infections.
    Hoberman A; Wald ER
    Pediatr Ann; 1999 Nov; 28(11):688-92. PubMed ID: 10578497
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
    Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
    J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and in vitro evaluation of cephalexin. A new orally administered cephalosporin antibiotic.
    Levison ME; Johnson WD; Thornhill TS; Kaye D
    JAMA; 1969 Sep; 209(9):1331-6. PubMed ID: 4895869
    [No Abstract]   [Full Text] [Related]  

  • 34. In vitro antimicrobial activity of several antimicrobial agents against Escherichia coli isolated from community-acquired uncomplicated urinary tract infections.
    Pignanelli S; Zaccherini P; Schiavone P; Nardi Pantoli A; Pirazzoli S; Nannini R
    Eur Rev Med Pharmacol Sci; 2013 Jan; 17(2):206-9. PubMed ID: 23377809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of urinary tract infections with cephalexin.
    Möhring K; Genster HG; Madsen PO
    J Urol; 1971 Nov; 106(5):757-60. PubMed ID: 4940185
    [No Abstract]   [Full Text] [Related]  

  • 36. Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Yilmaz E; Akalin H; Ozbey S; Kordan Y; Sinirtaş M; Gürcüoglu E; Ozakin C; Heper Y; Mistik R; Helvaci S
    J Chemother; 2008 Oct; 20(5):581-5. PubMed ID: 19028620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of cephalexin monohydrate in patients with uncomplicated urinary infections].
    Todd LE; Sepulveda C
    Prensa Med Mex; 1970; ():69-74. PubMed ID: 4931121
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical and bacteriological results in urinary tract infections with single-dose Ro 13-9904 (Rocephin).
    Seiler W; Stähelin HB; Böhni E
    Chemotherapy; 1981; 27 Suppl 1():80-92. PubMed ID: 7018854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical evaluation of cephalexin monohydrate in various bacterial infections].
    De La Cueva F; Ramirez Parra J
    Prensa Med Mex; 1970; ():23-6. PubMed ID: 4931112
    [No Abstract]   [Full Text] [Related]  

  • 40. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults.
    Jimenez-Cruz F; Jasovich A; Cajigas J; Jiang Q; Imbeault D; Woods GL; Gesser RM;
    Urology; 2002 Jul; 60(1):16-22. PubMed ID: 12100914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.